Head-to-head comparison
| Property | CagriSema | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~7 days (semaglutide component); cagrilintide ~7 days — both designed for weekly dosing | ~5 days |
| Mol. Weight | — | 4,813.45 Da |
| Side Effects | Nausea (very common, typically transient), Vomiting, Diarrhea | Nausea (up to 31%), Diarrhea, Vomiting |
Key differences
- Mechanism: CagriSema combines amylin signaling (satiety, gastric emptying) with GLP-1 signaling in two co-injected peptides; tirzepatide is a single molecule activating both GIP and GLP-1 receptors.
- Weight loss efficacy: REDEFINE-2 head-to-head trial showed CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg) achieved approximately 22.7% weight loss vs tirzepatide (15 mg) at approximately 20.2% over 72 weeks.
- Manufacturer: CagriSema is developed by Novo Nordisk; tirzepatide by Eli Lilly.
- Approval status: Tirzepatide is FDA-approved (Mounjaro/Zepbound); CagriSema is in Phase III trials.
- Injection format: CagriSema is two peptides co-formulated in one injection; tirzepatide is a single molecule in one injection. Both are once-weekly subcutaneous.
- Pathway novelty: CagriSema adds the amylin pathway (previously validated by pramlintide); tirzepatide adds the GIP pathway (a newer therapeutic target).
- GI side effects: Both show similar GI side effect profiles; CagriSema head-to-head trials showed comparable tolerability to tirzepatide.
The verdict
Head-to-head data from REDEFINE-2 suggests CagriSema produces modestly greater weight loss than tirzepatide (approximately 22.7% vs 20.2%). However, tirzepatide is FDA-approved and commercially available today, while CagriSema remains in trials. Both represent the frontier of multi-mechanism obesity therapy. The eventual market choice will depend on final approval data, pricing, insurance coverage, and individual patient response.
Frequently asked questions
The REDEFINE-2 head-to-head trial showed CagriSema achieved approximately 22.7% weight loss versus tirzepatide's approximately 20.2% over 72 weeks. This is a statistically significant difference, but both produce substantial weight loss. Final Phase III results will confirm this advantage.
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) co-formulated in a single subcutaneous injection. It combines two distinct satiety mechanisms in one weekly shot.
CagriSema is in Phase III trials by Novo Nordisk. If approved, it would be the first amylin/GLP-1 combination therapy for obesity. Specific FDA approval timelines are not confirmed as of 2026.
Head-to-head trials showed comparable GI side effect profiles (nausea, vomiting, diarrhea). CagriSema adds amylin-pathway effects, which are generally well-characterized from pramlintide experience. No major safety signals differentiated the two in available trial data.
CagriSema is not yet available for clinical use. If approved, switching between these therapies would require physician guidance. Both are weekly injections targeting different receptor combinations, so there is no direct dose equivalence.